Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Entrada Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 7 filings
- 4 insiders, $5.92M in total
- Insiders trading
- 4
- Net value
- −$5.92M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Entrada Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| MPM Bioventures 2018, L.P. | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2018 GP LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2018 LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| Gadicke Ansbert | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| Evnin Luke | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| Foley Todd | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2014, L.P. | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2014 (B), L.P. | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM Asset Management Investors BV2014 LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM Bioventures 2018 (B), L.P. | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM Asset Management Investors BV2018 LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2014 LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| MPM BioVentures 2014 GP LLC | 10% Owner | 3,885,115Indirect | Sep 9, 2026 | 4 |
| Doshi Dipal | CEO | 517,290 | Sep 3, 2026 | 2 |
| Dowden Nathan J | President & COO | 196,060 | Sep 3, 2026 | 4 |
| Sethuraman Natarajan | President, Research & Develop. | 214,238 | Sep 3, 2026 | 3 |
| Wentworth Kory James | Chief Financial Officer | 117,277 | Sep 3, 2026 | 6 |
| Parmar Kush | Director | 2,691,337Indirect | Aug 10, 2026 | 4 |
| Rocklage Scott M | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| Schwab Andrew J. | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| 5AM Ventures V, L.P. | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| 5AM Opportunities I, L.P. | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| 5AM Opportunities I (GP), LLC | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| 5AM Partners V, LLC | 10% Owner | 2,783,781 | Aug 10, 2026 | 3 |
| Kim Peter S | Director | 117,412 | Jun 12, 2026 | 1 |
| Thistle Mary | Director | – | Jun 12, 2026 | 1 |
| Zeiher Bernhardt G | Director | 5,000Indirect | Jun 12, 2026 | 2 |
| Chapman Gina | Director | – | Jun 12, 2026 | 1 |
| Radhakrishnan Maha | Director | – | Jun 12, 2026 | 1 |
| Baker Julian | 10% Owner | 4,691,392Indirect | Nov 24, 2025 | 2 |
| Baker Felix | 10% Owner | 4,691,392Indirect | Nov 24, 2025 | 2 |
| Baker Bros. Advisors LP | 10% Owner | 4,691,392Indirect | Nov 24, 2025 | 2 |
| Baker Bros. Advisors (GP) LLC | 10% Owner | 4,691,392Indirect | Nov 24, 2025 | 2 |
| Kreher Nerissa | Chief Medical Officer | 40,037 | Sep 6, 2023 | 0 |
| Crowley John F | Director | 5,000 | Jun 12, 2023 | 0 |
| Nuechterlein Carole | Director | – | Jun 6, 2022 | 0 |
| Roche Holding Ltd | 10% Owner | 2,813,525Indirect | Nov 4, 2021 | 0 |
| Roche Finance Ltd | 10% Owner | 2,813,525Indirect | Nov 4, 2021 | 0 |
| Redmile Group, LLC | 10% Owner | 1,954,420Indirect | Nov 4, 2021 | 0 |
| Green Jeremy | 10% Owner | 1,954,420Indirect | Nov 4, 2021 | 0 |
| Redmile Biopharma Investments III, L.P. | 10% Owner | 1,954,420Indirect | Nov 4, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2022 (view filing) | Sep 21-23 | 2 days | Doshi DipalPresident and CEO | SSale | −4.42K | $15.11 | −$66.9K | −2.0%215.4K after | 2 lots |
| Sep 23, 2022 (view filing) | Sep 21-23 | 2 days | Kreher NerissaChief Medical Officer | SSale | −4.28K | $15.08 | −$64.6K | −17.1%20.7K after | 2 lots |
| Sep 23, 2022 (view filing) | Sep 21-23 | 2 days | Dowden Nathan JChief Operating Officer | SSale | −4.29K | $15.12 | −$64.9K | −6.3%64.4K after | 2 lots |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Doshi DipalPresident and CEO | SSale | −200 | $15.04 | −$3.01K | −0.1%219.8K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Dowden Nathan JChief Operating Officer | SSale | −100 | $15.01 | −$1.50K | −0.1%68.6K after | |
| Sep 19, 2022 (view filing) | Sep 15 | 4 days | Kreher NerissaChief Medical Officer | SSale | −106 | $15.01 | −$1.59K | −0.5%20.7K after | |
| Sep 12, 2022 (view filing) | Sep 8-9 | 4 days | Doshi DipalPresident and CEO | SSale | −1.79K | $15.13 | −$27.0K | −0.8%220.0K after | 2 lots |
| Sep 12, 2022 (view filing) | Sep 8-9 | 4 days | Kreher NerissaChief Medical Officer | SSale | −2.02K | $15.11 | −$30.5K | −8.9%20.7K after | 2 lots |
| Sep 12, 2022 (view filing) | Sep 8-9 | 4 days | Dowden Nathan JChief Operating Officer | SSale | −1.78K | $15.11 | −$26.8K | −2.5%68.7K after | 2 lots |
| Aug 31, 2022 (view filing) | Aug 29-31 | 2 days | Doshi DipalPresident and CEO | SSale | −2.00K | $12.72 | −$25.4K | −1.0%206.7K after | 5 lots |
| Aug 26, 2022 (view filing) | Aug 24-25 | 2 days | Wentworth Kory JamesChief Financial Officer | SSale | −4.67K | $13.79 | −$64.4K | −29.8%11.0K after | 3 lots |
| Aug 23, 2022 (view filing) | Aug 19-23 | 4 days | Wentworth Kory JamesChief Financial Officer | SSale | −11.7K | $13.08 | −$152.5K | −44.5%14.5K after | 3 lots |
| Aug 18, 2022 (view filing) | Aug 16-18 | 2 days | Wentworth Kory JamesChief Financial Officer | SSale | −600 | $13.02 | −$7.81K | −2.9%20.2K after | 3 lots |
| Jul 29, 2022 (view filing) | Jul 27 | 2 days | Doshi DipalPresident and CEO | SSale | −2.00K | $12.00 | −$24.0K | −0.9%208.7K after | |
| Jun 29, 2022 (view filing) | Jun 27 | 2 days | Dowden Nathan JChief Operating Officer | SSale | −7.71K | $13.00 | −$100.3K | −10.6%64.9K after | |
| Jun 29, 2022 (view filing) | Jun 27 | 2 days | Doshi DipalPresident and CEO | SSale | −4.00K | $12.00 | −$48.0K | −1.9%210.7K after | |
| Jun 6, 2022 (view filing)5:07 PM ET | Jun 2-6 | 4 days | Baker Julian and 3 others10% Owner | PPurchase | +40.9K | $6.37 | +$260.8K | +0.9%4.50M after | 6 lots |
| May 24, 2022 (view filing)6:39 PM ET | May 20-24 | 4 days | Baker Julian and 3 others10% Owner | PPurchase | +48.5K | $5.82 | +$282.4K | +1.1%4.47M after | 10 lots |
| May 18, 2022 (view filing)5:38 PM ET | May 16-18 | 2 days | Baker Julian and 3 others10% Owner | PPurchase | +71.9K | $5.99 | +$430.7K | +1.7%4.42M after | 8 lots |
| Jan 13, 2022 (view filing) | Jan 12 | 1 day | Crowley John FDirector | PPurchase | +5.00K | $9.72 | +$48.6K | New position5.00K after | |
| Nov 5, 2021 (view filing) | Nov 2 | 3 daysLate | Parmar KushDirector, 10% Owner | PPurchase | +250.0K | $20.00 | +$5.00M | +28.3%1.13M after | Duplicate filing |
| Nov 4, 2021 (view filing)9:10 PM ET | Nov 2 | 2 days | Rocklage Scott M and 5 others10% Owner | PPurchase | +250.0K | $20.00 | +$5.00M | +28.3%1.13M after | |
| Nov 4, 2021 (view filing)9:00 PM ET | Nov 2 | 2 days | Redmile Group, LLC and 2 others10% Owner | PPurchase | +1.00M | $20.00 | +$20.0M | +104.8%1.95M after | |
| Nov 4, 2021 (view filing)5:38 PM ET | Nov 2 | 2 days | MPM Bioventures 2018, L.P. and 2 others10% Owner | PPurchase | +100.0K | $20.00 | +$2.00M | +2.3%4.43M after | Duplicate filing |
| Nov 4, 2021 (view filing)5:37 PM ET | Nov 2 | 2 days | Gadicke Ansbert and 8 others10% Owner | PPurchase | +100.0K | $20.00 | +$2.00M | +2.3%4.43M after | Duplicate filing |
| Nov 4, 2021 (view filing) | Nov 2 | 2 days | Foley ToddDirector, 10% Owner | PPurchase | +100.0K | $20.00 | +$2.00M | +2.3%4.43M after |